The Feasibility and Efficacy of Dose Timing (Morning vs Evening) of Temozolomide in the Treatment of Glioblastoma

Launched by OTTAWA HOSPITAL RESEARCH INSTITUTE · Feb 24, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating whether the time of day that patients take a medication called Temozolomide (TMZ) affects its effectiveness in treating glioblastoma, a type of brain cancer. Researchers believe that because our bodies have natural rhythms, taking medication in the morning or evening might make a difference in how well it works. In this study, participants will be randomly assigned to either take their medication in the morning or in the evening and will keep a diary to track when they take it. The main goal is to see if it’s practical for patients to take their medication at a specific time of day and to gather information that could help with future larger studies.

To be eligible for this trial, participants must be 18 years or older, have been newly diagnosed with a specific type of glioblastoma, and have undergone surgery to remove as much of the tumor as possible. They should also have completed radiation therapy and be ready to start treatment with TMZ. Participants will be asked to provide consent to join the study and will need to complete some questionnaires. This pilot study is important because it will help researchers understand the feasibility of this approach and plan for more extensive research in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 years of age or older
• • Newly diagnosed IDH-wildtype glioblastoma
• • Completed maximal safe brain tumor resection
• • Completed post-operative brain RT
• • Plan to proceed with up to 6 cycles of adjuvant TMZ within 8 weeks of completing post-operative RT
• • Able and willing to provide oral informed consent
• Exclusion Criteria:
• • Unable or unwilling to complete study questionnaires
• • Metastatic or incurable cancer other than IDH-wild type glioblastoma